Macular Degeneration Treatment: Anti-VEGF Injections, AREDS2, and Emerging Therapies

The Leading Cause of Irreversible Vision Loss After 50

Age-related macular degeneration (AMD) affects more than 20 million Americans and is the leading cause of irreversible central vision loss in adults over 50 in the developed world. The macula — a 5-millimeter region at the center of the retina responsible for sharp, color, and fine-detail vision — gradually deteriorates, eroding the ability to read, drive, and recognize faces while peripheral vision typically remains intact. AMD comes in two forms: the "dry" (atrophic) form, which accounts for roughly 85–90% of cases, and the "wet" (neovascular) form, which causes approximately 90% of severe vision loss despite being less prevalent.

The treatment you need depends entirely on which type you have.

Dry AMD: Slowing Progression With AREDS2

Dry AMD is characterized by the accumulation of drusen (protein and lipid deposits) beneath the retina and the progressive loss of retinal pigment epithelium (RPE) and photoreceptor cells. Advanced dry AMD culminates in geographic atrophy (GA) — large areas of RPE cell death with no current cure. Until 2023, slowing progression was the only available strategy.

The AREDS2 (Age-Related Eye Disease Study 2) formula, developed from two landmark NIH-funded clinical trials, remains the evidence-based standard for intermediate AMD and advanced AMD in one eye. The AREDS2 daily supplement combination is:

• Vitamin C: 500 mg
• Vitamin E: 400 IU
• Lutein: 10 mg (replacing beta-carotene, which increased lung cancer risk in smokers)
• Zeaxanthin: 2 mg
• Zinc oxide: 80 mg
• Cupric oxide: 2 mg (added to prevent zinc-induced copper deficiency)

AREDS2 supplements reduced the risk of AMD progressing to advanced stages by approximately 25% over five years in patients with intermediate AMD. They do not benefit patients with early AMD or no AMD.

Two drugs — pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay) — received FDA approval in 2023 specifically for geographic atrophy, the first treatments ever approved for dry AMD. Both are intravitreal injections targeting complement pathway proteins (C3 and C5, respectively) and demonstrated modest but statistically significant reductions in GA lesion growth rate in phase 3 trials.

Wet AMD: The Anti-VEGF Revolution

Wet AMD occurs when abnormal new blood vessels (choroidal neovascularization, or CNV) grow beneath the retina, driven by vascular endothelial growth factor (VEGF). These leaky vessels cause rapid, severe central vision loss — often within weeks to months without treatment. The introduction of anti-VEGF intravitreal injections in the mid-2000s transformed wet AMD from a condition causing almost certain legal blindness to one where vision can be stabilized or even improved.

Anti-VEGF therapy requires repeated intravitreal injections — an office procedure in which a needle delivers the drug directly into the vitreous cavity of the eye. While the phrase "eye injection" is understandably alarming, the procedure takes seconds, involves only topical anesthesia, and carries a low serious complication rate (endophthalmitis risk approximately 1 in 1,000–3,000 injections). The burden of treatment — monthly or near-monthly injections for potentially years — remains the primary quality-of-life challenge. Faricimab's dual mechanism and extended dosing intervals represent the most significant advance in reducing injection burden.

Laser and Photodynamic Therapies

Before anti-VEGF injections, laser photocoagulation and photodynamic therapy (PDT) were the primary treatments for wet AMD. Their roles have narrowed significantly but have not disappeared.

• Thermal laser photocoagulation: Destroys abnormal blood vessels with a thermal burn; effective but causes permanent laser scars in the visual field; now reserved for extrafoveal or juxtafoveal lesions not amenable to anti-VEGF therapy
• Photodynamic therapy (verteporfin/Visudyne): Verteporfin is injected intravenously and preferentially accumulates in CNV vessels; activation by low-energy laser light causes localized vessel thrombosis without thermal damage; still used in select cases, particularly polypoidal choroidal vasculopathy (PCV)

Emerging and Future Therapies

The next frontier in AMD treatment targets the underlying drivers of both dry and wet disease with approaches that could reduce injection burden or offer disease modification.

Gene therapy trials have shown that a single intravitreal injection of an AAV vector encoding an anti-VEGF protein can maintain suppression of CNV activity for 2+ years in early trials, potentially replacing the repeated injection burden that burdens tens of millions of patients worldwide. Results from pivotal trials are expected by 2027.

Lifestyle, Monitoring, and Risk Reduction

AMD has identifiable risk factors, several of which are modifiable. Cigarette smoking is the most powerful modifiable risk factor — smokers have 2–4× the AMD risk of non-smokers, and the risk persists for years after cessation. UV protection via wraparound sunglasses and broad-brimmed hats is widely recommended, though direct evidence is less robust. A Mediterranean-type diet rich in dark leafy vegetables, fish, and antioxidants is associated with reduced AMD risk in observational studies and forms the dietary basis of the AREDS2 supplement strategy.

Self-monitoring with an Amsler grid — a grid of straight lines with a central fixation dot — allows patients to detect new distortions or scotomas between clinical visits. Any sudden change in central vision warrants same-day ophthalmology evaluation, as wet AMD can convert from dry AMD rapidly, and early treatment preserves substantially more vision than delayed treatment.

This article is for informational purposes only. Consult a qualified healthcare professional before making medical decisions.